Skip to main content
Top

09-05-2024 | Photodynamic Therapy | Retinal Disorders

Three-year outcome of photodynamic therapy combined with VEGF inhibitor for pachychoroid neovasculopathy

Authors: Yoko Nomura, Shuichiro Aoki, Kohdai Kitamoto, Kohei Ueda, Keiko Azuma, Tatsuya Inoue, Ryo Obata

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology

Login to get access

Abstract

Background

Long-term results of photodynamic therapy (PDT) combined with vascular endothelial growth factor (VEGF) inhibitors for pachychoroid neovasculopathy (PNV) are not yet clear.

Methods

This study is a retrospective, observational case series. We retrospectively examined untreated PNV cases (22 cases, 22 eyes, mean age of 71.0 years) who underwent PDT therapy in combination with VEGF inhibitors followed by additional treatments with pro re nata protocol. Visual acuity, number of treatments, and time to recurrence were examined. In addition, foveal choroidal thickness and choroidal vascularity index (CVI) were evaluated in 13 of 22 patients who were followed up with SpectralisOCTR from baseline.

Results

Fifteen (68%) cases had polyps at baseline. LogMAR visual acuity averaged 0.24 ± 0.20 (range, − 0.079 to 0.82) at baseline and significantly improved after 1, 2, and 3 years (p = 0. 004, 0.0003, 0.002, respectively). Fourteen patients (64%) recurred, with an average time to recurrence of 1.8 ± 0.9 years. Foveal choroidal thickness decreased significantly after 1 year (average from 326 μm to 263 μm) and remained unchanged up to 3 years (255 μm). CVI also decreased after 1 year (average from 0.62 to 0.61) and remained unchanged until 3 years later (0.60).

Conclusions

We examined the 3-year course of PDT in combination with the VEGF inhibitor for untreated PNV. Visual acuity was improved, foveal choroidal thickness and CVI were decreased after 3 years.
Literature
19.
32.
go back to reference Bressler NM (1960) Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol Chic Ill 119:198–207 Bressler NM (1960) Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol Chic Ill 119:198–207
39.
go back to reference Takahashi K, Shiraga F, Ishida S et al (2015) Diagnostic criteria for atrophic age-related macular degeneration. Nippon Ganka Gakkai Zasshi 119:671–677PubMed Takahashi K, Shiraga F, Ishida S et al (2015) Diagnostic criteria for atrophic age-related macular degeneration. Nippon Ganka Gakkai Zasshi 119:671–677PubMed
48.
go back to reference Schmidt-Erfurth U, Laqua H, Schlötzer-Schrehard U et al (1960) (2002) Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol Chic Ill 120:835–844 Schmidt-Erfurth U, Laqua H, Schlötzer-Schrehard U et al (1960) (2002) Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol Chic Ill 120:835–844
Metadata
Title
Three-year outcome of photodynamic therapy combined with VEGF inhibitor for pachychoroid neovasculopathy
Authors
Yoko Nomura
Shuichiro Aoki
Kohdai Kitamoto
Kohei Ueda
Keiko Azuma
Tatsuya Inoue
Ryo Obata
Publication date
09-05-2024
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-024-06499-6